



## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Agency for Healthcare Research and Quality

#### Notice of Meetings

**AGENCY:** Agency for Healthcare Research and Quality (AHRQ), Department of Health and Human Services (HHS).

**ACTION:** Notice of five AHRQ subcommittee meetings.

**SUMMARY:** The subcommittees listed below are part of AHRQ's Health Services Research Initial Review Group (IRG) Committee. Grant applications are to be reviewed and discussed at these meetings. Each subcommittee meeting will be closed to the public.

**DATES:** See below for dates of meetings:

1. Healthcare Effectiveness and Outcomes Research (HEOR)  
Date: February 7-8, 2024
2. Healthcare Safety and Quality Improvement Research (HSQR)  
Date: February 7-8, 2024
3. Health System and Value Research (HSVR)  
Date: February 13-14, 2024
4. Healthcare Research Training (HCRT)  
Date: February 15-16, 19, 2024
5. Healthcare Information Technology Research (HITR)  
Date: February 29-March 1, 2024

#### ADDRESSES:

Agency for Healthcare Research and Quality (Virtual Review)

5600 Fishers Lane

Rockville, Maryland 20857

**FOR FURTHER INFORMATION CONTACT:** (to obtain a roster of members, agenda or minutes of the non-confidential portions of the meetings.)

Jenny Griffith

Committee Management Officer

Office of Extramural Research Education and Priority Populations

Division of Policy, Coordination and Analysis

Agency for Healthcare Research and Quality (AHRQ)

5600 Fishers Lane

Rockville, Maryland 20857

Telephone (301) 427-1557

**SUPPLEMENTARY INFORMATION:**

In accordance with section 10 (a)(2) of the Federal Advisory Committee Act (5 U.S.C. app. 2), AHRQ announces meetings of the above-listed scientific peer review groups, which are subcommittees of AHRQ's Health Services Research Initial Review Group Committee. The subcommittee meetings will be closed to the public in accordance with the provisions set forth in 5 U.S.C. app. 2 section 10(d), 5 U.S.C. 552b(c)(4), and 5 U.S.C. 552b(c)(6). The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Agenda items for these meetings are subject to change as priorities dictate.

Dated: December 20, 2023.

**Marquita Cullom,**

*Associate Director.*

[FR Doc. 2023-28506 Filed: 12/26/2023 8:45 am; Publication Date: 12/27/2023]